Aigen Investment Management, LP Chemo Centryx, Inc. Transaction History

Aigen Investment Management, LP

$487 Million
Q3 2024

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 02, 2022	BUY	$15.36 - $27.51 $124,016 - $222,115	8,074 New	8,074 $200,000
Q1 2022 May 05, 2022	SELL	$22.22 - $39.12 $311,302 - $548,071	-14,010 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$18.38 - $40.5 $257,503 - $567,405	14,010 New	14,010 $484,000
Q4 2020 Feb 12, 2021	SELL	$47.25 - $65.16 $2.92 Million - $4.02 Million	-61,740 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$46.35 - $61.69 $2.34 Million - $3.11 Million	50,380 Added 443.49%	61,740 $3.38 Million
Q2 2020 Aug 10, 2020	BUY	$38.58 - $65.07 $165,662 - $279,410	4,294 Added 60.77%	11,360 $654,000
Q1 2020 May 08, 2020	BUY	$32.73 - $50.78 $231,270 - $358,811	7,066 New	7,066 $284,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Aigen Investment Management, LP with notifications on news.